Patent · US Active

Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

US8242102B2 · kind B2 · utility

1Cited by

2References

23Claims

0Family size

Assignee

Abbott GmbH & Co. KG · DE

Inventors

Sean Colm Turner · Ludwigshafen, DE
Andreas Haupt · Ludwigshafen, DE
Wilfried Braje · Ludwigshafen, DE
Udo Lange · Ludwigshafen, DE
Karla Drescher · Ludwigshafen, DE
Karsten Wicke · Ludwigshafen, DE
Liliane Unger · Ludwigshafen, DE
Mario Mezler · Ludwigshafen, DE
Wolfgang Wernet · Ludwigshafen, DE
Matthias Mayrer · Biblis, DE

Key dates

Filing date	Mar 23, 2008
Grant date	Aug 14, 2012
Priority date	—
Expiry date	Aug 26, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.wherein

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.